Enrollment Temporarily Closed
This study is temporarily closed to new enrollments. Please contact the study team for more information or check back frequently.

Alliance A041701 (Acute Myeloid Leukemia) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out how an experimental drug called uproleselan works in your body and against your cancer.

What is the Condition Being Studied?

Acute Myeloid Leukemia (AML)

Who Can Participate in the Study?

Adults ages 60 and older who:
- Are diagnosed with AML
- Do not have a genetic defect in a receptor called FMS-like Tyrosine Kinase 3/FLT3
- Have not received chemotherapy
- Have no signs of brain or spinal cord involvement

Age Group

What is Involved?

If you join this study, you will:
- Be randomly assigned (50/50 chance, like flipping a coin) to either Group 1 or Group 2
-- Group 1 will get treatment with chemotherapy drugs (daunorubicin + cytarabine)
-- Group 2 will get treatment with chemotherapy drugs (daunorubicin + cytarabine) in addition to the study drug uproleselan
- Have blood draws
- Have a bone marrow sample taken
- Have scans to get images of your heart (echocardiogram)
- Receive the chemotherapy and study drug through a vein in your arm (IV)

Study Details

Full Title
Alliance A041701: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Principal Investigator
Hematologic Oncologist
Protocol Number
IRB: PRO00102302
NCT: NCT03701308
Phase II/III
Enrollment Status
Enrollment Temporarily Closed
More Information
Contact the Duke Recruitment Innovation Center